Implementation of two different experimental designs for screening and optimization of process parameters for metformin-loaded carboxymethyl chitosan formulation

Folic Acid Functionalized Diallyl Trisulfide–Solid Lipid Nanoparticles for Targeting Triple Negative Breast Cancer

“…DATS, solid lipid, and DATS-SLNs FT-IR spectra (area 4000–500 cm −1 ) were studied using an FT-IR spectrophotometer (Bruker Alpha-One, Bruker Optik, Ettlingen Germany) [ 33 ].…”

“…DATS-SLNs were screened to achieve a minimum PS ≤ 200 nm (particle size influences circulation time, particularly in narrow capillaries where blockage is possible), a narrower PDI value of ≤0.2, and a maximum entrapment efficiency (%EE), (%EE represents the estimated percentage of DATS as the difference between the initial DATS quantity and the unentrapped quantity of DATS in the supernatant with respect to the total amount incorporated in SLNs). Based on the drug’s solubilizing capacity in the lipid, the drug-to-lipid ratio and lipids were assessed for optimization [ 16 , 33 ].…”

“…Finally, based on early screening data, a three-level, 3 3 design (BBD) was selected for DATS-SLNs optimization [ 16 , 33 ]. The optimization was carried out by analyzing the relationship between dependent variables such as PS, PDI, and %EE and critical manufacturing attributes such as the quantity of palmitic acid, amount of surfactant Pluronic F-68, and concentration of co-surfactant soy lecithin, which were optimized at three levels: high, medium, and low ( Table 2 ).…”

“…The key function of the SLNs was to increase the DATS therapeutic efficacy and stability while ensuring a minimal PS and a high EE. The Malvern Zeta sizer (Nano ZS, Malvern Instruments, Worcestershire, UK) was used [ 33 ] to determine the PS (nm) and ZP (mV) of DATS-SLNs and FA-DATS-SLNs at 25 °C.…”

A Review on Drug Delivery System for Tumor Therapy

“…O-CMC-MET NPs induce apoptosis of MiaPaCa-2 cells mainly through the endogenous apoptotic pathway and affect cell cycle progression by downregulating the mRNA expression of p21, Vanin 1, and MMP9 (Snima et al, 2014). The optimized antitumor system of O-CMC-MET NPs is further embodied in breast cancer, which has better efficacy of the NPs compared with free MET for MCF-7 cells in a localized manner (De et al, 2019). MET-encapsulated positively charged liposomes (lipo-MET) could improve dose and activity of the drug, which significantly affected IC50 values, cell migration activity, colony formation, and apoptosis in MDA-MB-231 and MCF-7 cells (Shukla et al, 2019).…”